Sangamo Therapeutics ended 2024 with only enough cash to fund its operations into the first quarter of 2025, but CEO Sandy Macrae said he is confident an imminent deal for the company’s Fabry disease gene therapy candidate, isaralgagene civaparvovec (ST-920), will fund Sangamo through human proof-of-concept for its two lead wholly-owned genetic medicine programs.
Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline
New Hemophilia Partners Also Circling
Low on cash when Pfizer handed back rights to its hemophilia A gene therapy, Sangamo is talking to partners for its Fabry disease gene therapy to fund its two lead programs through proof-of-concept.
More from Deals
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
• By
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.